Results 71 to 80 of about 3,645,426 (307)

Improvement in the function of self-activating chimeric antigen receptor by replacing the linker sequence

Frontiers in Immunology
Chimeric antigen receptor (CAR)-T cell therapy is an effective treatment for hematological cancers; however, challenges remain in its application to solid tumors. Among these, the control of CAR-T cell exhaustion is important.
Taku Kouro, Taku Kouro, Daisuke Hoshino, Yasunobu Mano, Yasunobu Mano, Shoutaro Tsuji, Hidetomo Himuro, Hidetomo Himuro, Kohzoh Imai, Tetsuro Sasada, Tetsuro Sasada   +10 more
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Phase I/II Clinical Study of PRaG Regimen Combined With Intraperitoneal Infusion of PD-1 Inhibitor for Advanced Refractory Solid Tumors With Cancerous Ascites (PRaG4.0P Study)

Technology in Cancer Research & Treatment
Objective: The prognosis of malignant tumors with peritoneal metastases and cancerous ascites has generally been poor, with limited treatment options.
Yingying Xu MS, Yuehong Kong MS, Yifu Ma MS, Meiling Xu MS, Jiabao Yang MS, Junjun Zhang PhD, Rongzheng Chen MS, Guangqiang Chen MS, Zhihui Hong MS, Xiangrong Zhao MS, Chenyang Zhang MS, Pengfei Xing MS, Liyuan Zhang MD, Peifeng Zhao MS   +13 more
doaj   +1 more source

Reinstating endogenous antitumor immunity: The concept of therapeutic management of cancer

Forum of Clinical Oncology, 2016
Strong evidence points to the role of cancer immunoediting and tumor immune infiltrates in regulating cancer progression. By understanding the immune tumor microenvironment, we can now target key pathways that suppress endogenous antitumor responses ...
Pistamaltzian Nikolaos F., Perez Sonia A., Baxevanis Constantin N.   +2 more
doaj   +1 more source

Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization

Molecular Oncology, EarlyView.
In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu, Nicolas J. Niklaus, Anna M. Schläfli, Igor Tokarchuk, Magali Humbert, Federico La Manna, Bich Vu, David Maul, Ramin Radpour, Marianna Kruithof‐de Julio, Inti Zlobec, Jörn Dengjel, Bruce E. Torbett, Mario P. Tschan   +13 more
wiley   +1 more source

Osteopontin Blockade Immunotherapy Increases Cytotoxic T Lymphocyte Lytic Activity and Suppresses Colon Tumor Progression

, 2021
Human colorectal cancers are mostly microsatellite-stable with no response to anti-PD-1 blockade immunotherapy, necessitating the development of a new immunotherapy.
John D. Klement, Alyssa D. Merting, Chunwan Lu, Kebin Liu, Dakota B. Poschel, Dafeng Yang, Priscilla S. Redd   +6 more
core   +1 more source

Cancer‐associated mutations in endometriosis reframe a benign disease through molecular oncology

Molecular Oncology, EarlyView.
This review aims to comprehensively analyse cancer‐associated somatic mutations (CAMs) present in endometriotic lesions, emphasizing their biological roles, spatial distribution and implications for translational applications in medicine. By contextualizing a benign state within a genomic framework, this analysis seeks to establish its value as a ...
Clarissa Mujacic, Maria Concetta Vitale, Rita Siino, Emilia Di Giovanni, Carla Ferrante Bannera, Enrico Di Marco, Andrea Gottardo, Tancredi Didier Bazan Russo, Nadia Barraco, Alessandro Perez, Valerio Gristina, Antonio Galvano, Giuseppe Badalamenti, Antonio Russo, Viviana Bazan, Lorena Incorvaia   +15 more
wiley   +1 more source

Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease.

BACKGROUND: Intratumorally delivered immunotherapies have the potential to favorably alter the local tumor microenvironment and may stimulate systemic host immunity, offering an alternative or adjunct to other local and systemic treatments. Despite their
Andtbacka, RH, Coffin, R, Marabelle, A, Loi, S, Melero, I, Neyns, B, Kelly, CM, de Baere, T, Davar, D, Szapary, P, Sheth, RA, Long, GV, Bhardwaj, N, Kaufman, H, Brody, JD, Chesney, J, Solomon, SB, Khilnani, AD, Pinato, DJ, Harrington, KJ, Middleton, M, Goldmacher, G, Liu, K, de Gruijl, TD, Fury, M, Luke, JJ   +25 more
core   +1 more source

The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis

Scientific Reports
More promising, effective, and less-invasive biomarkers for PD(L)-1 targeted responses, immune-related adverse events (irAEs), and prognosis are being explored.
Xiaomin Fu, Fanghui Li, Hongqin You, Benling Xu, Tingjie Wang, Peng Qin, Lu Han, Yong Zhang, Fang Zhang, Lingdi Zhao, Baozhen Ma, Yiman Shang, Yonghao Yang, Zibing Wang, Jinrong Qu, Quanli Gao   +15 more
doaj   +1 more source

Enhancement of antitumor effect by peptide vaccine therapy in combination with anti-CD4 antibody: Study in a murine model

Biochemistry and Biophysics Reports, 2016
Purpose: The clinical efficacy of cancer peptide vaccine therapy is insufficient. To enhance the anti-tumor effect of peptide vaccine therapy, we combined this therapy with an anti-CD4 mAb (GK1.5), which is known to deplete CD4+ cells, including ...
Norihiro Fujinami, Toshiaki Yoshikawa, Yu Sawada, Manami Shimomura, Tatsuaki Iwama, Shiori Sugai, Shigehisa Kitano, Yasushi Uemura, Tetsuya Nakatsura   +8 more
doaj   +1 more source